TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

Ads

You May Also Like

Motif Bio to Present Iclaprim Data at ECCMID 2018

Phase 3 trial results for REVIVE-2 in patients with ABSSSIPotential cost savings opportunities with ...